HIV treatment and prevention on every 2026 California Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in California cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
12 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | HealthSpring Assurance Rx$0.00/moS5617-158 | Wellcare Value Script$5.70/moS4802-163 | Wellcare Classic$6.20/moS4802-094 | HealthSpring Extra Rx$70.60/moS5617-382 | SilverScript Choice$103.60/moS5601-064 | Humana Value Rx Plan$104.60/moS5884-211 | AARP Medicare Rx Saver from UHC$109.40/moS5921-376 | Humana Basic Rx Plan$132.20/moS5884-114 | AARP Medicare Rx Preferred from UHC$165.40/moS5921-413 | Humana Premier Rx Plan$172.90/moS5884-178 | Blue Shield Rx Plus$199.70/moS2468-003 | Blue Shield Rx Enhanced$227.80/moS2468-004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Dovatodolutegravir and lamivudine | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 429%QL 300/30d | Tier 440% | Tier 431% | Tier 430%QL 300/30d | Tier 433% | Tier 432%QL 180/30d | Tier 438%QL 180/30d | Tier 432%QL 180/30d | Tier 431%QL 180/30d | Tier 450%QL 180/30d | Tier 449%QL 6/1d | Tier 437%QL 6/1d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Julucadolutegravir and rilpivirine | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d | Tier 525%QL 1/1d | Tier 533%QL 1/1d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 429%QL 30/30d | Tier 440%QL 30/30d | Tier 431%QL 30/30d | Tier 430%QL 30/30d | Tier 433%QL 30/30d | Tier 432%QL 30/30d | Tier 438%QL 30/30d | Tier 432%QL 30/30d | Tier 431%QL 30/30d | Tier 450%QL 30/30d | Tier 449%QL 1/1d | Tier 437%QL 1/1d |
| Tivicaydolutegravir | Tier 429%QL 180/30d | Tier 525% | Tier 525% | Tier 430%QL 180/30d | Tier 525% | Tier 526%QL 60/30d | Tier 525%QL 60/30d | Tier 525%QL 60/30d | Tier 531%QL 60/30d | Tier 533%QL 60/30d | Tier 449%QL 6/1d | Tier 437%QL 6/1d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.